Medicines Stock Rating Lowered by Jefferies Group (MDCO)
Medicines (NASDAQ:MDCO) was downgraded by equities researchers at Jefferies Group from a “buy” rating to a “hold” rating in a research report issued on Thursday, TheFlyOnTheWall.com reports. They currently have a $27.00 price target on the stock, down from their previous price target of $38.50. Jefferies Group’s target price indicates a potential downside of 18.43% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at Zacks downgraded shares of Medicines from a “neutral” rating to an “underperform” rating in a research note on Tuesday, February 4th. They now have a $32.00 price target on the stock. Separately, analysts at RBC Capital raised their price target on shares of Medicines from $41.00 to $50.00 in a research note on Thursday, December 5th. They now have an “outperform” rating on the stock. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $37.13.
Shares of Medicines (NASDAQ:MDCO) traded down 11.54% on Thursday, hitting $29.28. The stock had a trading volume of 5,218,346 shares. Medicines has a 1-year low of $28.63 and a 1-year high of $41.28. The stock has a 50-day moving average of $36.88 and a 200-day moving average of $34.71. The company has a market cap of $1.734 billion and a P/E ratio of 55.17.
The Medicines Company is a pharmaceutical company focused on the treatment of critical care patients through the delivery of medicines to the global hospital marketplace.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.